Novartis CEO Vas Narasimhan stated the company will not join the weight loss drug market, focusing instead on unique areas like treatments for secondary effects of weight loss. Avoiding direct competition with major obesity drugmakers, Narasimhan highlighted Novartis’ research in reducing side effects and retaining muscle mass. The company aims to target winning areas like Alzheimer’s, Huntington’s, Parkinson’s, and cancer therapies, particularly its radioligand therapies, expecting to build a $20 billion business and maintain a distinct position in the market.
Full Article
Some OpenAI Employees Are About to Become Millionaires
OpenAI has facilitated a private stock sale with SoftBank Group, offering current and former employees the opportunity to sell their stock at $210 per share. SoftBank plans to purchase up to $1.6 billion in stock at the new $157 billion valuation, allowing current employees to sell up to $10 million worth of shares, giving preference to them over former staff if oversubscribed. The deadline for shareholders to decide on selling their shares is December 24....
Read more